Physician profile
Mark A Sims
NPI 1932103504
$2,923.95
in general payments reported to CMS, 2019-2025
20 companies · $32.10 in 2025
The $32.10 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $474 · 2021: $1,056 · 2022: $691 · 2025: $32.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $32.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $32.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.78 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $826.17 | 2019-2022 | |
| Gilead Sciences, INC. | $273.84 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.27 | 2019-2022 | |
| Janssen Biotech, INC. | $155.50 | 2019-2022 | |
| Amgen INC. | $107.25 | 2021-2022 | |
| Celgene Corporation | $75.08 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $62.32 | 2020-2021 | |
| Allergan, INC. | $52.10 | 2019 | |
| Intercept Pharmaceuticals, INC. | $49.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $33.69 | 2021-2022 | |
| Boston Scientific Corporation | $32.10 | 2025 | General - Kidney Stone Disease |
| Shionogi INC | $30.58 | 2019 | |
| Braintree Laboratories, INC. | $30.01 | 2019-2021 | |
| Vivus LLC | $20.66 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $17.65 | 2020 | |
| Nestle Healthcare Nutrition INC. | $15.88 | 2022 | |
| Qol Medical, LLC | $14.10 | 2019 | |
| Ucb, INC. | $13.45 | 2019 | |
| W. L. Gore & Associates, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.